



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration Silver Spring MD 20993

February 26, 2019

Ms. Guoying Tan Sr.Director of Regulatory Affairs Sunshine Lake Pharma Co., Ltd. Northern Industry Road 1#, Song Shan Lake, Dongguan, 523808 Guangdong, China

Sent via email to:tanguoying@hecpharm.com

Dear Petitioner:

Your petition to the Food and Drug Administration requesting that the Commissioner declare that the drug product Lacosamide Granules for Oral Solution, 10 mg/mL is suitable for submission as an abbreviated new drug application was received by this office on 02/26/2019.

It was assigned docket number FDA-2019-P-0915. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby Supervisory Administrative Proceedings Specialist Division of Dockets Management FDA/Office of the Executive Secretariat (OES)